R&D News | pharmaphorum

News

Jounce setback casts deeper pall over ICOS as cancer target

A phase 2 trial of Jounce Therapeutics' ICOS agonist vopratelimab has ended in failure, casting further doubt about the validity of ICOS as a target for cancer therapies.

News

Futura eyes FDA filing as topical ED drug passes phase 3 tes...

Futura Medical's development of a topical treatment for erectile dysfunction (ED) is approaching the finish line in the US, as the UK biotech reports confirmatory phase 3 data ahead of an F

News

Phase 3 trial confirms Lumakras role in lung cancer

Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for

News

ESC22: AstraZeneca's Farxiga DELIVERs in heart failure

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patie

News

ESC22: Smartphone screening doubles atrial fibrillation dete...

A study as shown that a smartphone app has been found to be more effective than standard screening approaches in detecting atrial fibrillation (AF) among a population of older individuals i

News

ESC22: Despite trial misses, Bayer preps phase 3 for asundex...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.

Jounce setback casts deeper pall over ICOS as cancer target

Futura eyes FDA filing as topical ED drug passes phase 3 tes...

Phase 3 trial confirms Lumakras role in lung cancer

ESC22: AstraZeneca's Farxiga DELIVERs in heart failure

ESC22: Smartphone screening doubles atrial fibrillation dete...

ESC22: Despite trial misses, Bayer preps phase 3 for asundex...

Five indications added to Pharmacy First prescribing scheme

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks